EMA Authorised: Tevimbra (tislelizumab) — Beone Medicines Ireland Limited

View source ↗

Summary

EMA authorised Tevimbra (tislelizumab) from Beone Medicines Ireland Limited for multiple cancer indications, including esophageal squamous cell carcinoma, non-s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma
• Gastric Cancer
• Nasopharyngeal Carcinoma
• Non-small Cell Lung Cancer
• Small Cell Lung Cancer

Drugs mentioned

• TEVIMBRA (tislelizumab-jsgr)

Snippet

Status: Authorised. Therapeutic area: Esophageal Squamous Cell Carcinoma;Carcinoma, Non-Small-Cell Lung;Small Cell Lung Carcinoma;Nasopharyngeal Carcinoma;Stomach Neoplasms. MAH: Beone Medicines Ireland Limited. Decision date: 24/10/2025